Dalcetrapib or JTT-705 is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012. The drug was aimed at raising the blood levels of good cholesterol (cholesterol carried in HDL particles aka HDL-C).
This page contains content from the copyrighted Wikipedia article "Dalcetrapib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
